ARG Oncology Webinar
How to Make Adaptive Dose-Finding Trials Easy for the Clinician
On March 11, 2021, Atlantic Research Group, an oncology CRO focusing on early phase trials, presented a webinar via Xtalks that focused on helping to make adaptive dose-finding trials easier. Below you can find a video and transcript of the event.
Key takeaways from the event:
- Make clinical programs more precise without making them more complicated
- The math is intricate but that should not be a deterrent to the clinician’s decisions
- The best chance at clinical success is correct dosing as soon as possible
- Reaching MTD in a streamlined way can be done without wishful thinking or fear
John Friend, MD, Chief Medical Officer, Cellectar Biosciences, Inc.
Dr. Friend has more than 17 years of global drug development and medical affairs expertise in hematology/oncology as well as a variety of other therapeutic indications. He is currently the Chief Medical Officer of Cellectar Biosciences, leading its research and development, clinical, medical affairs and regulatory affairs divisions.
Ed Schnipper, MD, Head of Clinical Development, X-37
Dr. Schnipper is a widely recognized expert in innovative design and management of clinical trials, in several indications, particularly in oncology. He has established a reputation for being able to determine quickly and cost-effectively as to whether a drug is safe and effective. Currently the Head of Clinical Development at X-37, Dr. Schnipper has played key roles in drug development from IND to NDA in diverse organizations.
Michael Wisniewski, PhD, Vice-President of Biostatistics and Informatics, Atlantic Research Group
Dr. Wisniewski has over 30 years of experience as a statistician in clinical research. He is currently the VP or Biostatistics and Data Informatics at ARG. Previously, he held similar positions at Covance (formerly Chiltern), PPD and GSK where he has built and led international teams of statisticians.